---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-077361"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2024-09-10T23:59:59+00:00"
generated_at: "2026-05-31T05:34:17.942279+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# ABVC Biopharma regains compliance with Nasdaq Shareholder Approval Rules

## Summary
- Received Nasdaq notification on Sept 6, 2024 confirming compliance with Listing Rules 5635(a)(1) and 5635(a)(2).
- Compliance based on Board Resolution dated May 16, 2024.
- Regained compliance for continued listing on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001213900-24-077361
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2024-09-10T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390024077361/0001213900-24-077361-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390024077361/ea0214114-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-077361
- JSON: https://secwatch.observer/filing/0001213900-24-077361.json
- Plain text: https://secwatch.observer/filing/0001213900-24-077361.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.